Since the drug’s approval and launch earlier this year, J&J has recorded more than 20,000 patient starts on Icotyde, funneled ...
Rather than another instance of on-shoring enthusiasm, ARPA-H’s personalized RNA drug production network project should be ...
UCB is encouraging people with immunology-driven diseases such as hidradenitis suppurativa (HS), plaque psoriasis and ...
Drug-device maker Kaléo has secured a federal contract worth $96.1 million, enlisting in an effort to bolster U.S. biodefense ...
Shares of Syndax Pharmaceuticals have tumbled 17% after a phase 2 flop | Syndax and Incyte are cutting their idiopathic ...
One in two women is unaware that hormonal fluctuations during perimenopause and menopause can affect their skin, a Galderma ...
Roughly half a year after the close of its deal to acquire Bayer spinout AiCurus, Asahi Kasei’s $920 million bet has paid off ...
Less than four years after returning to Bausch + Lomb to lead the eye health company following its split from Bausch Health, ...
Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
Most manufacturers know Inmar for pharmacy returns and consumer drug takeback programs. | Emily Welker explains how retail ...
Arcutis Biotherapeutics has lined up another celeb to tout the benefits of its topical skin medicine Zoryve, adding ...
Generic drugmaker Viatris is beefing up its pain medicine portfolio with a $1.65 billion deal to buy Pacira BioSciences and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results